GW Pharmaceuticals Dette/Equité
Quel est le Dette/Equité de GW Pharmaceuticals?
Le Dette/Equité de GW Pharmaceuticals est 1.27
Quelle est la définition de Dette/Equité?
Le ratio d'endettement et d'équité est un ratio financier indiquant la proportion relative des capitaux propres et de la dette utilisée pour financer les actifs d'une entreprise.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Dette/Equité des entreprises dans Health Care secteur sur NASDAQ par rapport à GW Pharmaceuticals
Entreprises avec dette/equité similaire à GW Pharmaceuticals
- MMTC a Dette/Equité de 1.27
- European Cobalt a Dette/Equité de 1.27
- Boozt AB (publ) a Dette/Equité de 1.27
- Boozt AB (publ) a Dette/Equité de 1.27
- Allreal AG a Dette/Equité de 1.27
- Mazda Motor a Dette/Equité de 1.27
- GW Pharmaceuticals a Dette/Equité de 1.27
- Sky Industries a Dette/Equité de 1.27
- Avidian Gold a Dette/Equité de 1.27
- OM a Dette/Equité de 1.27
- Kontron Ag O.N a Dette/Equité de 1.27
- Itafos a Dette/Equité de 1.27
- Satia Industries a Dette/Equité de 1.27